Highlights Cingulate Inc.

Equities

CING

US17248W2044

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.761 ^USD	-14.01%		-21.11%	-90.05%

May. 08	Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Certain Pre-Funded Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Cingulate Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Cingulate Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Global markets live: Meta, Amazon, Apple, Tesla, Intel...	Feb. 02
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTX-2103	Dec. 01	CI
Cingulate Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Cingulate Inc. to Host CNS Key Opinion Leader Panel in New York City Expert Analysis of Cingulate, it?s Phase 3 ADHD Adult Data, Anxiety, and PTR? Drug Delivery Platform Innovations	23-10-19	CI
Cingulate Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Cingulate Inc. Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for Adhd	23-07-11	CI
Cingulate Inc. Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August	23-06-29	CI
Cingulate Completes Phase 3 Adult Trial of Ctx-1301 (Dexmethylphenidate) for Adhd	23-06-08	CI
Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Cingulate Inc. Announces Successful Transfer of its Proprietary PTR Manufacturing Processes for its Lead Candidate, CTx-1301 to Societal CDMO, Inc	23-05-03	CI
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (Dexmethylphenidate) for ADHD	23-04-04	CI
Cingulate, Indegene Sign Joint Commercialization Agreement for Lead ADHD Candidate	23-03-13	MT
Cingulate Inc. and Indegene Announces Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301	23-03-13	CI
Cingulate Posts Wider Q4 Loss, Reviews Options to Raise Capital	23-03-10	MT
CINGULATE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-10	AQ
Cingulate Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
Cingulate Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cingulate Inc.

Equities

CING

US17248W2044

Highlights

Filters